Electroconvulsive Therapy Decreases Dopamine D<sub>2</sub>Receptor Binding in the Anterior Cingulate in Patients With Depression

Saijo, Tomoyuki; Takano, Akihiro; Suhara, Tetsuya; Arakawa, Ryosuke; Okumura, Masaki; Ichimiya, Tetsuya; Ito, Hiroshi; Okubo, Yoshiro

doi:10.4088/jcp.08m04746blu

Cited by 60 publications

(37 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Psychosis is particularly common in patients with advanced PD who have been treated with dopaminergic agonists for long durations (27). Similarly to typical antipsychotics, ECT likely exerts its antipsychotic effect through attenuated D2 signaling (28), as ECT has been shown to reduce D2 receptor binding in the anterior cingulate (29). Furthermore, ECT may produce an antipsychotic effect through reduced 5HT2A receptor density (30).…”

Section: Discussionmentioning

confidence: 99%

Unilateral ultra-brief pulse electroconvulsive therapy for depression in Parkinson's disease

et al. 2016

View full text Add to dashboard Cite

Objectives Electroconvulsive therapy (ECT) has demonstrated efficacy in treating core symptoms of Parkinson’s disease (PD), however widespread use of ECT in PD has been limited due to concern over cognitive burden. We investigated the use of a newer ECT technology known to have fewer cognitive side effects (right unilateral (RUL) ultrabrief pulse (UBP)) for the treatment of medically-refractory psychiatric dysfunction in PD. Materials and methods This open label pilot study included 6 patients who were assessed in the motoric, cognitive and neuropsychiatric domains prior to and after RUL UBP ECT. Primary endpoints were changes in total score on the HAM-D-17 and GDS-30 rating scales. Results Patients were found to improve in motoric and psychiatric domains following RUL UBP ECT without cognitive side effects, both immediately following ECT and at 1-month follow-up. Conclusions This study demonstrates that RUL UBP ECT is safe, feasible and potentially efficacious in treating multiple domains of PD, including motor and mood, without clear cognitive side effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Unilateral ultra-brief pulse electroconvulsive therapy for depression in Parkinson's disease

et al. 2016

View full text Add to dashboard Cite

show abstract

“…An MRI study of 12 patients found that hippocampal volumes increased signifi cantly after ECT, supporting the hypothesis that hippocampus may play a central role in the treatment of depression (Nordanskog et al, 2010). A positron emission tomography (PET) study showed that electroconvulsive therapy decreased D(2) receptor binding in the rostral anterior cingulate in depressed patients responding to ECT (Saijo et al, 2010b).…”

Section: What Is the Mechanism Of Action?mentioning

confidence: 82%

The Use of ECT and MST in treating depression

Allan

Ebmeier

2011

International Review of Psychiatry

View full text Add to dashboard Cite

Electroconvulsive therapy (ECT) has been used clinically since 1938. Its most common use is in the treatment of depression: fi rst line treatment where rapid recovery is a priority, but more frequently as an effective treatment for patients who do not respond to pharmacological and psychological approaches. Whilst it is widely hailed as an effective treatment, concerns about its effect on cognition remain. The development of magnetic seizure therapy (MST) over the past decade has attempted to devise a therapy with comparable effi cacy to ECT, but without the associated cognitive side effects. The rationale for this is that MST uses magnetic fi elds to induce seizures in the cortex, without electrical stimulation of brain structures involved with memory. MST has been used successfully in the treatment of depression, yet there is a dearth of literature in comparison with ECT. We present a systematic review of the literature on ECT (from 2009ECT (from -2011 and MST (from 2001MST (from -2011.

show abstract

“…Saijo et al scanned seven MDD patients' brain after six to seven ECTs using PET to examine the effect of treatment on dopamine D 2 receptors. They found significant increase in D 2 receptors of anterior cingulate of patients who received ECT [60]. Although these studies show regulatory role of serotonergic and dopaminergic pathways in biologi cal mechanisms involved in response to ECT, it is yet to be discovered how ECT causes these alterations.…”

Section: Effect Of Adjunctive Psychotropic Drugs On Ect Outcomementioning

confidence: 96%

Pharmacogenetics in Electroconvulsive Therapy and Adjunctive Medications

et al. 2015

View full text Add to dashboard Cite

Electroconvulsive therapy (ECT) has shown apparent efficacy in treatment of patients with depression and other mental illnesses who do not respond to psychotropic medications or need urgent control of their symptoms. Pharmacogenetics contributes to an individual's sensitivity and response to a variety of drugs. Clinical insights into pharmacogenetics of ECT and adjunctive medications not only improves its safety and efficacy in the indicated patients, but can also lead to the identification of novel treatments in psychiatric disorders through understanding of potential molecular and biological mechanisms involved. In this review, we explore the indications of pharmacogenetics role in safety and efficacy of ECT and present the evidence for its role in patients with psychiatric disorders undergoing ECT.

show abstract

Electroconvulsive Therapy Decreases Dopamine D₂Receptor Binding in the Anterior Cingulate in Patients With Depression

Abstract: Electroconvulsive therapy decreased D(2) receptor binding in the rostral AC in MDD patients responding to ECT. Our finding suggests that one of the biologic mechanisms of ECT could be related to dopaminergic alteration in the rostral AC.

Cited by 60 publications

References 0 publications

Unilateral ultra-brief pulse electroconvulsive therapy for depression in Parkinson's disease

Unilateral ultra-brief pulse electroconvulsive therapy for depression in Parkinson's disease

The Use of ECT and MST in treating depression

Pharmacogenetics in Electroconvulsive Therapy and Adjunctive Medications

Contact Info

Product

Resources

About

Electroconvulsive Therapy Decreases Dopamine D2Receptor Binding in the Anterior Cingulate in Patients With Depression

Abstract: Electroconvulsive therapy decreased D(2) receptor binding in the rostral AC in MDD patients responding to ECT. Our finding suggests that one of the biologic mechanisms of ECT could be related to dopaminergic alteration in the rostral AC.

Cited by 60 publications

References 0 publications

Unilateral ultra-brief pulse electroconvulsive therapy for depression in Parkinson's disease

Unilateral ultra-brief pulse electroconvulsive therapy for depression in Parkinson's disease

The Use of ECT and MST in treating depression

Pharmacogenetics in Electroconvulsive Therapy and Adjunctive Medications

Contact Info

Product

Resources

About

Electroconvulsive Therapy Decreases Dopamine D₂Receptor Binding in the Anterior Cingulate in Patients With Depression